stars 1 stars 2 stars 3

KogeneBiotech is a leading company in the in-vitro diagnostics industry and has developed the 1st SARS-CoV-2 Real-time PCR Kit in South Korea, January 2020. We are a representative with a significant contribution in the early diagnosis and prevention of the spread of COVID-19 successfully. KogeneBiotech – the first mover of the Real-time PCR assay – has developed more than 1,000 PCR Kits. As a result, we have established an extensive product portfolio in emerging diseases, clinical diagnostics, food safety, animal diseases, and pathogens. We strive to ensure and improve public healthcare while maintaining continuous cooperation with the government authorities, the national research institutes, the great hospitals, and medical centers.

KogeneBiotech Questions

The KogeneBiotech annual revenue was $1 million in 2026.

Myoah Baek is the Vice President of KogeneBiotech.

6 people are employed at KogeneBiotech.

The NAICS codes for KogeneBiotech are [541713, 54171, 5417, 54, 541].

The SIC codes for KogeneBiotech are [87, 873].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users